We are live on
!
Find out more
Westfield Capital Management Portfolio holdings
AUM
$23.8B
1-Year Est. Return
49.45%
This Fund
S&P 500
This Quarter
Est. Return
+6.64%
1 Year Est. Return
+49.45%
3 Year Est. Return
+148.08%
5 Year Est. Return
+180.9%
10 Year Est. Return
+972.24%
AUM
$13.4B
AUM Growth
+$421M
(+3.2%)
Cap. Flow
-$231M
Cap. Flow
% of AUM
-1.73%
Top 10 Holdings %
Top 10 Hldgs %
18.95%
Holding
286
New
38
Increased
90
Reduced
103
Closed
43
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Thermo Fisher Scientific
TMO
|
+$95.8M |
| 2 |
Mettler-Toledo International
MTD
|
+$89.4M |
| 3 |
Bristol-Myers Squibb
BMY
|
+$66.9M |
| 4 |
Carnival Corporation Ltd
CCL
|
+$64.4M |
| 5 |
Walt Disney
DIS
|
+$62.3M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Steris
STE
|
+$102M |
| 2 |
Abbott
ABT
|
+$97.9M |
| 3 |
MGM Resorts International
MGM
|
+$97.5M |
| 4 |
Bank of America
BAC
|
+$90.9M |
| 5 |
Philip Morris
PM
|
+$88.2M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 21.01% |
| 2 | Healthcare | 16.54% |
| 3 | Industrials | 13.55% |
| 4 | Financials | 11.42% |
| 5 | Consumer Discretionary | 11.42% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
101
Hilton Worldwide
HLT
$70.9B
| $43.1M | 0.32% |
+543,942
| New | +$44.2M |
|
|
CTLT
102
DELISTED
CATALENT, INC.
CTLT
| $42.6M | 0.32% |
+1,016,914
| New | +$41.1M |
|
103
Integra LifeSciences
IART
$1.39B
| $41.7M | 0.31% |
647,601
-106,465
| -14% | -$6.59M |
|
104
Idexx Laboratories
IDXX
$46.4B
| $41.7M | 0.31% |
191,373
-42,934
| -18% | -$8.85M |
|
105
Burlington
BURL
$23.4B
| $41.3M | 0.31% |
274,640
-9,506
| -3% | -$1.35M |
|
106
Alexandria Real Estate Equities
ARE
$8.75B
| $41.1M | 0.31% |
326,110
-940
| -0.3% | -$117K |
|
107
Commault Systems
CVLT
$5.43B
| $40.6M | 0.3% |
615,984
+192,397
| +45% | +$13.2M |
|
108
Vail Resorts
MTN
$5.28B
| $39.8M | 0.3% |
145,110
-87,033
| -37% | -$21.3M |
|
109
Boyd Gaming
BYD
$6.21B
| $39.6M | 0.3% |
1,143,560
-38,985
| -3% | -$1.37M |
|
110
Raymond James Financial
RJF
$34.3B
| $39.6M | 0.3% |
665,369
+78,038
| +13% | +$4.84M |
|
111
Caesars Entertainment
CZR
$6.09B
| $39.3M | 0.29% |
1,004,259
-321,955
| -24% | -$13.3M |
|
112
MasTec
MTZ
$21.5B
| $39.1M | 0.29% |
770,669
+290,379
| +60% | +$14M |
|
|
XLRN
113
DELISTED
Acceleron Pharma
XLRN
| $38.6M | 0.29% |
795,043
-579,155
| -42% | -$21.1M |
|
|
GRA
114
DELISTED
W.R. Grace & Co.
GRA
| $37.6M | 0.28% |
513,463
-17,722
| -3% | -$1.24M |
|
115
Autodesk
ADSK
$50B
| $37.6M | 0.28% |
286,801
-43,979
| -13% | -$5.83M |
|
116
Crane NXT
CXT
$3.14B
| $37.5M | 0.28% |
1,347,176
+155,601
| +13% | +$4.68M |
|
117
NetApp
NTAP
$37.2B
| $37.3M | 0.28% |
475,031
+121,381
| +34% | +$8.54M |
|
118
Zoetis
ZTS
$31.8B
| $37M | 0.28% |
434,705
-2,855
| -0.7% | -$241K |
|
119
PVH
PVH
$4.09B
| $36.9M | 0.28% |
246,784
+7,414
| +3% | +$1.17M |
|
120
Gartner
IT
$11.8B
| $36.9M | 0.28% |
277,306
+39,151
| +16% | +$5.01M |
|
|
CLVS
121
DELISTED
Clovis Oncology, Inc.
CLVS
| $36.5M | 0.27% |
802,068
+251,753
| +46% | +$12.2M |
|
|
FLIR
122
DELISTED
FLIR Systems, Inc. (DE) Common Stock
FLIR
| $36.2M | 0.27% |
697,027
-17,338
| -2% | -$926K |
|
123
Orion
OEC
$369M
| $36.2M | 0.27% |
1,171,913
-36,902
| -3% | -$1.07M |
|
124
Palo Alto Networks
PANW
$294B
| $36M | 0.27% |
1,051,734
-137,100
| -12% | -$4.57M |
|
125
Robert Half
RHI
$4.02B
| $35.9M | 0.27% |
552,167
-15,458
| -3% | -$980K |
|
Similar funds
OAG
JG
CHP
SC
Westfield Capital Management's Q2 2018 Portfolio in Review
As of Q2 2018, Westfield Capital Management held 286 positions worth $13.4B, up 3.2% from $13B the previous quarter. Its ten largest holdings account for 19% of the portfolio.
Westfield Capital Management's Q2 2018 filing shows 38 new, 90 increased, 103 reduced and 43 closed positions. Its largest new stake was Bristol-Myers Squibb: 1,238,227 shares worth $68.5M. The largest sale was Steris, an estimated $102M.
By sector, the portfolio is most concentrated in Technology at 21% of assets, up from 21% a quarter earlier, followed by Healthcare and Industrials.
- Westfield Capital Management's largest Q2 2018 buy was Bristol-Myers Squibb: 1,238,227 shares worth $68.5M.
- Westfield Capital Management added most to Thermo Fisher Scientific in Q2 2018, an estimated $95.8M increase.
- Westfield Capital Management's biggest Q2 2018 reduction was Steris, cutting an estimated $102M.
- Westfield Capital Management fully exited MGM Resorts International in Q2 2018, selling an estimated $97.5M.
- Westfield Capital Management's ten largest holdings make up 19% of its $13.4B portfolio in Q2 2018.
- Westfield Capital Management opened 38 new positions and closed 43 in Q2 2018.
- Westfield Capital Management's portfolio value rose 3.2% quarter-over-quarter to $13.4B.
Based on Westfield Capital Management's 13F filing for Q2 2018, filed 13 Aug 2018.